Novartis AG has secured Medicaid coverage for a pricey new sickle cell disease therapy in two U.S. states just weeks after winning U.S. approval, following an early campaign to convince local officials of its value, according to a company executive and a Reuters review of public filings. The …
Recent Posts
Most Popular
StanChart’s South Korea troubles deepen after exotic notes backfire
STANDARD Chartered stuck it out in South Korea’s hotly contested consumer banking market while its global rivals threw in the towel one by one....
Work It Podcast: Why do Gen Z layoffs look so dramatic?
This generation is willing to share their experience online because they feel that it holds companies accountable for their actions, says our guest.
Bitcoin developers are touting ‘programmability’ as the catalyst for the next rally
AFTER the long-anticipated launch of US Bitcoin exchange-traded funds in January, and the once-every-four-years software update called the “halving” last month, the big question...
Kiwi looks to RBNZ rate decision to build on bullish momentum
NEW Zealand’s dollar is poised to extend recent gains and rally towards its March high as concern over elevated inflation damps expectations for interest-rate...